Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.

被引：0
|
作者：
Raje, Noopur S.
Leleu, Xavier P.
Lesokhin, Alexander M.
Mohty, Mohamad
Nooka, Ajay K.
Leip, Eric
Conte, Umberto
Viqueira, Andrea
Manier, Salomon
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Harvard Med Sch, Boston, MA USA
[2] CHU Poitiers, Hop Miletrie, Pole Reg Cancerol, Poitiers, France
[3] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA
[4] Sorbonne Univ, Hop St Antoine, Paris, France
[5] INSERM, UMRs938, Paris, France
[6] Emory Univ Hosp, Winship Canc Inst, Atlanta, GA USA
[7] Pfizer Inc, Cambridge, MA USA
[8] Pfizer Inc, New York, NY USA
[9] Pfizer SLU, Madrid, Spain
[10] CHU Lille, Lille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8040
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Raab, M. S.
    Haenel, M.
    Mohty, M.
    Tomasson, M. H.
    Arnulf, B.
    Bahlis, N. J.
    Prince, H. M.
    Niesvizky, R.
    Rodriguez-Otero, P.
    Martinez-Lopez, J.
    Koehne, G.
    Jethava, Y.
    Gabayan, A. E.
    Stevens, D. A.
    Nooka, A. K.
    Raje, N.
    Iida, S.
    Leip, E.
    Conte, U.
    Czibere, A.
    Viqueira, A.
    Lesokhin, A. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
  • [32] Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies
    Elmeliegy, Mohamed
    Lon, Hoi Kei
    Wang, Diane
    Ma, Wei An
    King, Lindsay
    Viqueira, Andrea
    Czibere, Akos
    BLOOD, 2023, 142
  • [33] Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Tomasson, Michael H.
    Bahlis, Nizar J.
    Costello, Caitlin
    Raje, Noopur S.
    Levy, Moshe Y.
    Dholaria, Bhagirathbhai R.
    Solh, Melhem M.
    Damore, Michael A.
    Jiang, Sibo
    Xie, Tao
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward Michael
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Gasparetto, Cristina
    Chu, Michael
    Dalovisio, Andrew Peter
    Sebag, Michael
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, A. Eli
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur S.
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos Gabor
    Viqueira, Andrea
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] MagnetisMM-30: A Phase 1B, Open-Label Study of Elranatamab in Combination With Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander
    Raza, Muhammed
    Acosta, Jorge
    Mueller, Patrick Y.
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S187 - S187
  • [36] MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
    Lesokhin, Alexander M.
    Raza, Muhammed Saleem
    Acosta, Jorge
    Muller, Patrick
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    Service, Myeloma
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Berenson, James R.
    Silagan, Noemi
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando J.
    Forouzan, Eli
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Boccia, Ralph V.
    Yang, Honghao Hank
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2020, 136
  • [38] Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naive to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
    Bahlis, Nizar Jacques
    Tomasson, Michael H.
    Mohty, Mohamad
    Niesvizky, Ruben
    Nooka, Ajay K.
    Manier, Salomon
    Maisel, Christopher
    Jethava, Yogesh
    Martinez-Lopez, Joaquin
    Prince, H. Miles
    Arnulf, Bertrand
    Rodriguez Otero, Paula
    Koehne, Guenther
    Touzeau, Cyrille
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Leip, Eric
    Sullivan, Sharon
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander M.
    BLOOD, 2022, 140
  • [39] BUDGET IMPACT OF ELRANATAMAB-BCMM IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE UNITED STATES
    Shah, B.
    Sandin, R.
    Liu, Y.
    Hu, Y.
    Schepart, A.
    Hughes, D.
    Hart, J.
    Hlavacek, P.
    VALUE IN HEALTH, 2024, 27 (06) : S136 - S136
  • [40] Safety and Efficacy of Elranatamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series
    Vianna, Pedro
    Bianchi, Giada
    Miller, Shannon
    Hossain, Shahrier
    Cuddy, Sarah
    Falk, Rodney
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S216 - S216
12345